Overview

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Collaborator:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Antidepressive Agents
Brexpiprazole